iBio's Non-GLP Non-human Primate Pharmacokinetics Study Suggests IBIO-600, Anti-myostatin Antibody Designed For Subcutaneous Administration, Could Provide A Significantly Extended Half-life In Humans And A Weight Loss Treatment Option While Preser...

-9.18%

iBio, Inc.

IBIO

0.89

-9.18%

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days.
Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist.
iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.